Cynbiose will attend the 3rd workshop on Probiotics and Gut Microbiotia – Lyon, February 4th 2020

Key event organized by Lyonbiopole, the “Probiotics and Intestinal Microbiota Day” brings together academic, clinical and industrial players (SMEs and large groups), around a thematic lecture on the modulation of the intestinal microbiota.

For this 3rd edition, the central theme “Yesterday’s antibiotics, next-generation probiotics and other new strategies for modulating the intestinal microbiota” will provide an opportunity to highlight product developments and their future challenges.

Contact us to meet our team during this day.


Cynbiose will be attending BIO Europe Spring – Paris, March 23-25th, 2020

Contact us to arrange a meeting and discuss about your preclinical projects.


Cynbiose, Signia Therapeutics and the VirPath academic laboratory are partnering on an ambitious collaborative R&D project to advance the development of innovative therapeutic treatments in the field of respiratory infections.

The METABIOSE project aims to develop and characterize a translational model of metapneumovirus
infection (hMPV), then to validate in preclinical studies a drug repositioned as a pneumovirus inhibitor
from Signia Therapeutics’s portfolio, as well as a new nebulization delivery thanks to an approved
medical device.

Read the press release.


Cynbiose attends BioFIT – Marseille, December 10 & 11th, 2019

We are attending BioFIT in Marseille, a unique European event gathering academics, TTOs and research institutions.

We will be pleased to meet you there, contact us to arrange a meeting.

BioFIT website:

Cynbiose will attend I4ID congress – Lyon, December 4-5th 2019

Meet our scientific team at the third edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2019) taking place at the ENS in Lyon, France.

Contact us to arrange a meeting.

More information on

Cynbiose will attend BIO Europe – Hamburg, November 11-13th 2019

We are attending BIO Fall in Germany. We will be pleased to meet you there, contact us to arrange a meeting.

Cynbiose attends the 3rd scientific workshop of the MARVELOUS project in the field of stroke – Lyon, October 4 2019

Cynbiose will present a new model and non invasive imaging results during the scientific communication on  “PET/MRI measurements of perfusion and blood brain barrier permeability in a stroke model”.

Cynbiose is part of the MARVELOUS project dedicated to « New MR imAging to pReVent cErebraL and myocardial reperfUSion injury »,

More information :

Symposium “Innovative & integrated solution providers in translational research to develop immunotherapies” – Paris, September 30th 2019

Register for this one-day workshop co-organized by Cynbiose, Oncodesign, Aepodia, CERB and PharmaLex : an unparalleled network of key partners.

Don’t miss this unique event with keynote lectures and roundtables discussions to support your drug development projects. Cynbiose will lead the roundtable discussion  ” Unlocking the potential of immunotherapies and vaccines : relevance of non-human primates models”.

More information and registration on this event that will take place on Monday September 30th, 2019 (Maison de la Chimie, Paris (France):


Cynbiose attends the 7th Antibody Industrial Symposium (AIS) in Tours.

Tours, June 24-25th, 2019 – Cynbiose will be attending the AIS congress ( whose topic is «Harnessing the Immune System with Therapeutic Antibodies».
The topics covered this year are:

  • Harnessing the Immune System with Immunomodulatory therapeutic Antibodies
  • Immunomodulation via cell membrane Antigens
  • Pitch Session Immunomodulation with mAbs : New Strategies & Technologies
  • Immunomodulation via Soluble Antigens
  • Immunomodulation via FC-FcgammaR interaction

Contact us to meet during the congress.

Cynbiose (FR) and Motac Neurosciences (UK, CN) sign a strategic partnership in metabolic disorders.

Lyon, January 8th, 2019 – Cynbiose SAS and Motac Neurosciences Ltd, two CRO specialised in preclinical services for the biopharmaceutical industry sign a strategic partnership to commercialize an integrated offer for exploratory and pharmacokinetics studies.

Both companies also agreed to co-develop innovative and proprietary preclinical models in metabolic disorders.

Contact us for more information.